Actavis’ Warner Chilcott Buy Brings Switch Options In Diversified Portfolio
This article was originally published in The Pink Sheet Daily
Actavis’ acquisition of Warner Chilcott creates a women’s health powerhouse with Rx-to-OTC switch potential. UBS analysts expect $400 million in cost synergies and an “even more robust than previously disclosed” pipeline and diverse product portfolio that complements Actavis’ existing products.
You may also be interested in...
Meanwhile, companies like Mylan and Novartis also reportedly have joined the Actavis chase. In addition, there’s been deal-making news from Elan and Theravance, Merck-Serono and Quintiles, and AbbVie and Alvine.
Merck’s Oxytrol for Women has the opportunity to “create the market” for OTC overactive bladder drugs, as well as encourage other switches for chronic, progressive conditions, marketing consultant Joe McGovern says. The transdermal patch product is slated to launch in September.
Watson adds Actavis for $5.6 bil.; Recordati buys OTCs in Germany; DoJ weighs in on Plan B case; NARC rebranded as ASRC; Korean lawmakers miss another chance on OTC bill; more news In Brief.